Ascendis pharma a/sASND.US Overview

US StockHealthcare

(No presentation for ASND)

Overview AI Analysis Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ASND Overall Performance

ASND AI Analysis & Strategy

ASND Recent Performance

0.42%

Ascendis pharma a/s

2.27%

Avg of Sector

0.07%

S&P500

ASND PowerScanner

ASND Key Information

ASND Valuation Metrics

ASND Earnings Table

ASND Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.